Sandbox g16
Dosage adjustment in patients with hepatic disease Return to Top
Dosage adjustment may be required in the presence of hepatic disease for the following medications (consult FDA package insert for details):
| Antimicrobial Agent | Category | Recommendation |
|---|---|---|
| Abacavir | Antiviral agent | A dose of 200 mg abacavir administered twice daily is recommended for patients with mild liver disease. The safety, efficacy, and pharmacokinetics of abacavir have not been studied in patients with moderate or severe hepatic impairment; therefore, abacavir is contraindicated in these patients. |
| Atazanavir | ||
| Caspofungin | ||
| Ceftriaxone | ||
| Chloramphenicol | ||
| Clindamycin | ||
| Darunavir | ||
| Delavirdine | ||
| Efavirenz | ||
| Enfuvirtide | ||
| Fosamprenavir | ||
| Fusidic acid | ||
| Indinavir | ||
| Isoniazid | ||
| Itraconazole | ||
| Lopinavir-Ritonavir | ||
| Metronidazole | ||
| Nafcillin | ||
| Nelfinavir | ||
| Nevirapine | ||
| Quinupristin-Dalfopristin | ||
| Rifabutin | ||
| Rifampin | ||
| Rimantadine | ||
| Ritonavir | ||
| Telithromycin | ||
| Tigecycline | ||
| Tinidazole | ||
| Voriconazole |